Svetlana Nikic, Founder of Precision Oncology Consulting, shared a post on LinkedIn:
“Just came across these ‘Personalised Cancer Medicine Flashcards 2025’ (published July 2025) by Universidad Autónoma de Madrid and Fundación Instituto Roche – this concise resource lists, across 9 major cancer types, the biomarkers considered ‘Standard’ (based on therapies currently approved and reimbursed by the Spanish National Health System) versus those ‘Recommended’ by FDA/EMA.
Why is this relevant? Because the gap between clinical guidelines and real-world reimbursement remains one of the biggest challenges for both pharma and diagnostic market access teams.
These flashcards are a great quick-reference tool for understanding where innovation meets barriers in practice, and where access efforts should focus.
This connects directly with the insights developed by Precision Oncology Consulting – Spanish Healthcare and Reimbursement Mapping Insights.”
Title: Personalised Cancer Medicine Flashcards 2025
Authors: Ramon Colomer, Rebeca Mondéjar, Nuria Romero-Laorden, Patricia Toquero, Berta Hernández, Jacobo Rogado
Read the Full Article.
More posts featuring Svetlana Nikic on OncoDaily.
